{"id":"https://openalex.org/W2599284751","doi":"https://doi.org/10.1017/s1092852917000074","title":"Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study","display_name":"Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study","alternate_titles":[],"publication_year":2017,"publication_date":"2017-03-30","ids":{"openalex":"https://openalex.org/W2599284751","doi":"https://doi.org/10.1017/s1092852917000074","mag":"2599284751","pmid":"https://pubmed.ncbi.nlm.nih.gov/28357969"},"language":"en","primary_location":{"id":"doi:10.1017/s1092852917000074","doi":"https://doi.org/10.1017/s1092852917000074","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852917000074","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/2953A10771A5080C043D7F5532C58AF2/S1092852917000074a.pdf/div-class-title-lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2599284751"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/2953A10771A5080C043D7F5532C58AF2/S1092852917000074a.pdf/div-class-title-lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study-div.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103816856","display_name":"Joyce Tsai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joyce Tsai","raw_affiliation_strings":["1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","institution_ids":["https://openalex.org/I4210122020"]},{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109331301","display_name":"Michael E. Thase","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael E. Thase","raw_affiliation_strings":["2Perelman School of Medicine of the University of Pennsylvania,Philadelphia,Pennsylvania,USA","Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Perelman School of Medicine of the University of Pennsylvania,Philadelphia,Pennsylvania,USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112141907","display_name":"Yongcai Mao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongcai Mao","raw_affiliation_strings":["1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","institution_ids":["https://openalex.org/I4210122020"]},{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003582081","display_name":"Daisy Ng\u2010Mak","orcid":"https://orcid.org/0000-0002-9802-7660","observed_orcids":["https://orcid.org/0000-0002-9802-7660"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daisy Ng-Mak","raw_affiliation_strings":["1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","institution_ids":["https://openalex.org/I4210122020"]},{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Andrei Pikalov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrei Pikalov","raw_affiliation_strings":["1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","institution_ids":["https://openalex.org/I4210122020"]},{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066553937","display_name":"Antony D Loebel","orcid":"https://orcid.org/0000-0002-7591-8647","observed_orcids":["https://orcid.org/0000-0002-7591-8647"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Antony Loebel","raw_affiliation_strings":["1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sunovion Pharmaceuticals Inc.,Fort Lee,New Jersey,and Marlborough,Massachusetts,USA","institution_ids":["https://openalex.org/I4210122020"]},{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, and Marlborough, Massachusetts, USA","institution_ids":["https://openalex.org/I4210122020"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5066553937"],"corresponding_institution_ids":["https://openalex.org/I4210122020"],"apc_list":{"value":3550,"currency":"USD","value_usd":3550},"apc_paid":{"value":3550,"currency":"USD","value_usd":3550},"fwci":0.963,"has_fulltext":true,"cited_by_count":25,"citation_normalized_percentile":{"value":0.69759072,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"22","issue":"2","first_page":"236","last_page":"245"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.01679999940097332,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lurasidone","display_name":"lurasidone","score":1.0},{"id":"https://openalex.org/keywords/anxiety","display_name":"anxiety","score":0.5740000009536743},{"id":"https://openalex.org/keywords/atypical-depression","display_name":"atypical depression","score":0.7570000290870667},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.7459999918937683},{"id":"https://openalex.org/keywords/depressive-symptoms","display_name":"depressive symptoms","score":0.5149999856948853},{"id":"https://openalex.org/keywords/mood-stabilizers","display_name":"mood stabilizers","score":0.4519999921321869}],"concepts":[{"id":"https://openalex.org/C2776701107","wikidata":"https://www.wikidata.org/wiki/Q416992","display_name":"Lurasidone","level":4,"score":0.9635316133499146},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.7386423349380493},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6757692098617554},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.5811668038368225},{"id":"https://openalex.org/C2777696351","wikidata":"https://www.wikidata.org/wiki/Q5644839","display_name":"Hamilton Anxiety Rating Scale","level":3,"score":0.5677688121795654},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48441439867019653},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.48083433508872986},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4607006907463074},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.40274694561958313},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3517732620239258},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.09029713273048401},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.08650597929954529},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000066553","descriptor_name":"Problem Behavior","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D000069056","descriptor_name":"Lurasidone Hydrochloride","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069056","descriptor_name":"Lurasidone Hydrochloride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000374","descriptor_name":"Aggression","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000374","descriptor_name":"Aggression","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D011594","descriptor_name":"Psychometrics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1017/s1092852917000074","doi":"https://doi.org/10.1017/s1092852917000074","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852917000074","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/2953A10771A5080C043D7F5532C58AF2/S1092852917000074a.pdf/div-class-title-lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},{"id":"pmid:28357969","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28357969","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS spectrums","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1017/s1092852917000074","doi":"https://doi.org/10.1017/s1092852917000074","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852917000074","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/2953A10771A5080C043D7F5532C58AF2/S1092852917000074a.pdf/div-class-title-lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2599284751.pdf","grobid_xml":"https://content.openalex.org/works/W2599284751.grobid-xml"},"referenced_works_count":62,"referenced_works":["https://openalex.org/W422260766","https://openalex.org/W590310416","https://openalex.org/W1563799145","https://openalex.org/W1592385480","https://openalex.org/W1966819687","https://openalex.org/W1970563784","https://openalex.org/W1971410477","https://openalex.org/W1971440513","https://openalex.org/W1972105422","https://openalex.org/W1972566307","https://openalex.org/W1977455682","https://openalex.org/W1979374243","https://openalex.org/W1988237057","https://openalex.org/W1992694138","https://openalex.org/W1994548103","https://openalex.org/W1995450583","https://openalex.org/W1999543065","https://openalex.org/W2000732451","https://openalex.org/W2014357401","https://openalex.org/W2015990248","https://openalex.org/W2018460930","https://openalex.org/W2032918847","https://openalex.org/W2037090579","https://openalex.org/W2038822165","https://openalex.org/W2051239765","https://openalex.org/W2054318560","https://openalex.org/W2068629754","https://openalex.org/W2070280532","https://openalex.org/W2071666535","https://openalex.org/W2073010232","https://openalex.org/W2074339845","https://openalex.org/W2094778965","https://openalex.org/W2097121947","https://openalex.org/W2107950329","https://openalex.org/W2113560690","https://openalex.org/W2121573844","https://openalex.org/W2125412819","https://openalex.org/W2131185010","https://openalex.org/W2131823335","https://openalex.org/W2135949575","https://openalex.org/W2137044087","https://openalex.org/W2146659162","https://openalex.org/W2146917485","https://openalex.org/W2159857896","https://openalex.org/W2160070901","https://openalex.org/W2161726793","https://openalex.org/W2163368530","https://openalex.org/W2165707326","https://openalex.org/W2167659819","https://openalex.org/W2170684975","https://openalex.org/W2275487654","https://openalex.org/W2324187437","https://openalex.org/W2340083175","https://openalex.org/W2346986627","https://openalex.org/W2387175684","https://openalex.org/W2395115132","https://openalex.org/W2400172486","https://openalex.org/W2400600349","https://openalex.org/W2403845770","https://openalex.org/W2764311721","https://openalex.org/W4323284061","https://openalex.org/W6659779955"],"related_works":["https://openalex.org/W4410089331","https://openalex.org/W2726675883","https://openalex.org/W2370809794","https://openalex.org/W2596603828","https://openalex.org/W2113560690","https://openalex.org/W4407387121","https://openalex.org/W4379141242","https://openalex.org/W4416407563","https://openalex.org/W2750125546","https://openalex.org/W3044851204"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1,35],"aim":[2],"of":[3,12,32,45,78,105,225,255],"this":[4,38,222],"post-hoc":[5,223],"analysis":[6,39,224],"was":[7,92,133,149,187,237],"to":[8,75,110],"evaluate":[9,102],"the":[10,48,95,103,112],"efficacy":[11],"lurasidone":[13,83,148,186,236],"in":[14,37,129,159,197,242,248],"treating":[15],"patients":[16,46,164,202],"with":[17,22,27,54,65,81,147,151,165,185,189,203,228,235,239,250],"major":[18],"depressive":[19,244],"disorder":[20],"(MDD)":[21],"mixed":[23,140,229],"features":[24,230],"who":[25,72],"present":[26],"mild":[28,119,167,205,251],"and":[29,122,176,212,231,245,252],"moderate-to-severe":[30,123,177,213,253],"levels":[31,254],"anxiety.":[33],"METHODS:":[34],"data":[36],"were":[40,73,117],"derived":[41],"from":[42,127],"a":[43,55,139,152,190],"study":[44],"meeting":[47],"DSM-IV-TR":[49],"criteria":[50],"for":[51,135,142,163,201],"unipolar":[52],"MDD,":[53],"Montgomery-\u00c5sberg":[56],"Depression":[57],"Rating":[58,98],"Scale":[59,99],"(MADRS)":[60],"total":[61,131,161,199],"score":[62,132,162,200],"\u226526,":[63],"presenting":[64],"two":[66,114],"or":[67,87],"three":[68],"protocol-defined":[69],"manic":[70],"symptoms,":[71],"randomized":[74],"6":[76,155,193],"weeks":[77],"double-blind":[79],"treatment":[80,234],"either":[82],"20-60":[84],"mg/day":[85],"(n=109)":[86],"placebo":[88,158,196],"(n=100).":[89],"Anxiety":[90,97],"severity":[91],"evaluated":[93],"using":[94,138],"Hamilton":[96],"(HAM-A).":[100],"To":[101],"effect":[104,173],"baseline":[106,128],"anxiety":[107,115,120,124,168,178,206,214,232,246,256],"on":[108],"response":[109],"lurasidone,":[111],"following":[113],"groups":[116],"defined:":[118],"(HAM-A\u226414)":[121],"(HAM-A\u226515).":[125],"Change":[126],"MADRS":[130,160],"analyzed":[134],"each":[136],"group":[137],"model":[141],"repeated":[143],"measures.":[144],"RESULTS:":[145],"Treatment":[146,184],"associated":[150,188,238],"significant":[153,191,240],"week":[154,192],"change":[156,194],"versus":[157,195],"both":[166,204,243],"(-18.4":[169],"vs.":[170,180,208,216],"-12.8,":[171],"p<0.01,":[172,210],"size":[174],"[ES]=0.59)":[175],"(-22.0":[179],"-13.0,":[181],"p<0.001,":[182],"ES=0.95).":[183],"HAM-A":[198],"(-7.6":[207],"-4.0,":[209],"ES=0.62),":[211],"(-11.4":[215],"-6.1,":[217],"p<0.0001,":[218],"ES=0.91).":[219],"CONCLUSIONS:":[220],"In":[221],"an":[226],"MDD":[227],"population,":[233],"improvement":[241],"symptoms":[247],"subgroups":[249],"at":[257],"baseline.":[258]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2599284751","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-04-07T00:00:00"}
